

## ASX/Media Release

6 June 2019

### Botanix at the Jefferies Healthcare Conference

**Philadelphia PA and Sydney Australia, 6 June 2019:** Medical dermatology company Botanix Pharmaceuticals (“Botanix” or “the Company”) is pleased to announce that its Founder and Executive Director, Matt Callahan, will be presenting the Company’s progress at the 2019 Jefferies Healthcare Conference in New York. Mr Callahan’s presentation is attached to this release.

Jefferies Group is the largest independent full-service global investment banking firm headquartered in the U.S. The conference features company presentations, thematic panel discussions, and one-on-one meetings. Last year, the event attracted more than 2,600 attendees from around the world.

Mr Callahan will provide an update on the progress of Botanix’s late stage clinical programs, including the acne study (Phase 2), atopic dermatitis study (Phase 2) and the psoriasis mechanism of action study (Phase 1b) which remain on track for data read outs in 3Q CY2019, 4Q CY2019 and 2Q CY2019, respectively. The conference will also allow Botanix to establish links with various investors and potential strategic partners.

### About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a clinical stage medical dermatology company based in Perth, Australia and Philadelphia, PA. The Company’s focus is the development of safe and effective topical treatments for acne, psoriasis, atopic dermatitis and other skin conditions. The active ingredient contained in Botanix products is a synthetic form of a widely studied natural compound. Treatment targets include inflammation, deterioration of the of the skin barrier, skin cell proliferation, pruritus (itch), excess sebum production and bacterial infection.

Botanix has an exclusive license to use a proprietary drug delivery system (Permetrex™) for direct skin delivery of active pharmaceuticals in all skin diseases. Botanix is working with multiple parties to test the application of Permetrex™ on both a fee-for-service and traditional license basis.

Botanix pursues a rapid clinical development strategy aimed at accelerating product commercialisation. The patient treatment duration of clinical studies is generally completed within a 4 to 12-week timeframe.

The Company completed its first acne patient studies with BTX 1503 in January 2018 and has commenced a Phase 2 clinical study in June 2018 with data read-out expected in Q3 2019. The BTX 1204 atopic dermatitis Phase 2 patient study is also underway with enrolment expected to be

completed in 3Q CY2019. Finally, Phase 1b BTX 1308 psoriasis mechanism of action study is nearing completion with data anticipated to be available in 2Q CY2019. Pipeline projects that leverage the anti-microbial properties of cannabidiol are also moving forward and are planned to enter the clinic in 2H 2019.

To learn more please visit: <https://www.botanixpharma.com/>

**For more information, please contact:**

**General enquiries**

Matt Callahan  
Botanix Pharmaceuticals  
Founder & Executive Director

+1 215 767 4184

[mcallahan@botanixpharma.com](mailto:mcallahan@botanixpharma.com)

**Investor enquiries**

Joel Seah  
Vesparum Capital

P: +61 3 8582 4800

[botanixpharma@vesparum.com](mailto:botanixpharma@vesparum.com)

**Media enquiries**

Haley Chartres  
Hales<sup>2</sup> Communications

P: +61 423 139 163

[haley@h-squared.com.au](mailto:haley@h-squared.com.au)